Global and India Recombinant Influenza Vaccine Market Report & Forecast 2024-2034
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global and India Recombinant Influenza Vaccine Market Report & Forecast 2024-2034
Recombinant technology plays an important role in the preparation of influenza vaccines. It allows scientists to create and express specific influenza virus proteins through genetic engineering to prepare influenza vaccines. This approach typically involves inserting the genetic sequence of the influenza virus into an expression system, enabling it to produce viral antigen proteins, and then using these proteins to prepare a vaccine.
The global Recombinant Influenza Vaccine revenue was US$ 106.8 million in 2022 and is forecast to a readjusted size of US$ 188.4 million by 2029 with a CAGR of 8.5% during the forecast period (2024-2034).
In India, the Recombinant Influenza Vaccine revenue is expected to grow from US$ million in 2022 to US$ million by 2029, at a CAGR of % during the forecast period (2024-2034).
A significant driver in the Influenza Vaccine market is the growing awareness of the importance of vaccination in preventing seasonal and pandemic influenza outbreaks. As healthcare organizations and governments worldwide promote vaccination as a crucial public health measure, there is an increasing demand for influenza vaccines. Additionally, advances in vaccine research and development, including the production of more effective and broader-spectrum vaccines, are driving market growth. One of the key challenges in this market is the need for frequent vaccine updates to match evolving influenza strains. The virus undergoes genetic changes, requiring annual adjustments to vaccine formulations. This presents logistical challenges for manufacturers in terms of timely production and distribution. Vaccine hesitancy and misinformation also pose challenges by impacting vaccination rates and public perception. Lastly, ensuring equitable access to vaccines, especially in low-income and underserved populations, remains a persistent challenge in the fight against influenza.
This report focuses on global and India Recombinant Influenza Vaccine market, also covers the segmentation data of other regions in regional level and county level.
India is now the world’s most populous country. According to IMF (its July update to its World Economic Outlook), India’s GDP growth is projected at 6.1% in 2024, powered by domestic investment. First and foremost, the key factor in India's rapid economic growth is the huge supply and demand from a large population base. Demand and supply sides working in both directions to support India's economic stability.
India is a market full of opportunities, and the demand for Recombinant Influenza Vaccine will continue to grow rapidly in the future.
Global Recombinant Influenza Vaccine Scope and Market Size
Recombinant Influenza Vaccine market is segmented in regional and country, by players, by type and by application. Companies, stakeholders, and other participants in the global Recombinant Influenza Vaccine market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by type and by application for the period 2018-2029.
For India market, this report focuses on the Recombinant Influenza Vaccine market size by players, by Type and by Application, for the period 2018-2029. The key players include the global and local players, which play important roles in India.
Sanofi
Segment by Type
Vial
Prefilled
Public Sector
Private Sector
By Region
Americas
United States
Canada
Mexico
Brazil
China
APAC (excluding China)
Japan
South Korea
China Taiwan
ASEAN
India
EMEA
Europe
Middle East
Africa
Chapter 1Introduces Recombinant Influenza Vaccine definition, global sales (volume and revenue), India market size, India percentage in global market. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 2Provides the analysis of various market segments by type, covering the volume, price, revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3Provides the analysis of various market segments by application, covering the revenue, price, volume, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4Detailed analysis of Recombinant Influenza Vaccine companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Revenue and volume of Recombinant Influenza Vaccine in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 6Americas by type, by application and by country, sales, and revenue for each segment.
Chapter 7EMEA by type, by application and by region, sales, and revenue for each segment.
Chapter 8China by type, by application, sales, and revenue for each segment.
Chapter 9APAC (excluding China) by type, by application and by region, sales, and revenue for each segment.
Chapter 10Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Recombinant Influenza Vaccine sales, revenue, gross margin, and recent development, etc.
Chapter 11Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 12Research findings and conclusion
The global Recombinant Influenza Vaccine revenue was US$ 106.8 million in 2022 and is forecast to a readjusted size of US$ 188.4 million by 2029 with a CAGR of 8.5% during the forecast period (2024-2034).
In India, the Recombinant Influenza Vaccine revenue is expected to grow from US$ million in 2022 to US$ million by 2029, at a CAGR of % during the forecast period (2024-2034).
A significant driver in the Influenza Vaccine market is the growing awareness of the importance of vaccination in preventing seasonal and pandemic influenza outbreaks. As healthcare organizations and governments worldwide promote vaccination as a crucial public health measure, there is an increasing demand for influenza vaccines. Additionally, advances in vaccine research and development, including the production of more effective and broader-spectrum vaccines, are driving market growth. One of the key challenges in this market is the need for frequent vaccine updates to match evolving influenza strains. The virus undergoes genetic changes, requiring annual adjustments to vaccine formulations. This presents logistical challenges for manufacturers in terms of timely production and distribution. Vaccine hesitancy and misinformation also pose challenges by impacting vaccination rates and public perception. Lastly, ensuring equitable access to vaccines, especially in low-income and underserved populations, remains a persistent challenge in the fight against influenza.
This report focuses on global and India Recombinant Influenza Vaccine market, also covers the segmentation data of other regions in regional level and county level.
India is now the world’s most populous country. According to IMF (its July update to its World Economic Outlook), India’s GDP growth is projected at 6.1% in 2024, powered by domestic investment. First and foremost, the key factor in India's rapid economic growth is the huge supply and demand from a large population base. Demand and supply sides working in both directions to support India's economic stability.
India is a market full of opportunities, and the demand for Recombinant Influenza Vaccine will continue to grow rapidly in the future.
Global Recombinant Influenza Vaccine Scope and Market Size
Recombinant Influenza Vaccine market is segmented in regional and country, by players, by type and by application. Companies, stakeholders, and other participants in the global Recombinant Influenza Vaccine market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by type and by application for the period 2018-2029.
For India market, this report focuses on the Recombinant Influenza Vaccine market size by players, by Type and by Application, for the period 2018-2029. The key players include the global and local players, which play important roles in India.
By Company
Sanofi
Segment by Type
Vial
Prefilled
Segment by Application
Public Sector
Private Sector
By Region
Americas
United States
Canada
Mexico
Brazil
China
APAC (excluding China)
Japan
South Korea
China Taiwan
ASEAN
India
EMEA
Europe
Middle East
Africa
Chapter Introduction
Chapter 1Introduces Recombinant Influenza Vaccine definition, global sales (volume and revenue), India market size, India percentage in global market. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 2Provides the analysis of various market segments by type, covering the volume, price, revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3Provides the analysis of various market segments by application, covering the revenue, price, volume, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4Detailed analysis of Recombinant Influenza Vaccine companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Revenue and volume of Recombinant Influenza Vaccine in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 6Americas by type, by application and by country, sales, and revenue for each segment.
Chapter 7EMEA by type, by application and by region, sales, and revenue for each segment.
Chapter 8China by type, by application, sales, and revenue for each segment.
Chapter 9APAC (excluding China) by type, by application and by region, sales, and revenue for each segment.
Chapter 10Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Recombinant Influenza Vaccine sales, revenue, gross margin, and recent development, etc.
Chapter 11Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 12Research findings and conclusion
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices